Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant Infection

Noah Shopen, Michal Dekel, Michal Mizrahi, Efrat Zandberg, Nancy Bishouty, Daniel Talmud, Ben Vaknin, Shira Haberman, Malka Katz Shalhav, David Zeltser, Neta Cohen
doi: https://doi.org/10.1101/2022.01.29.22270090

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Back to top
Posted January 31, 2022.
Download PDF
Data/Code
Email
Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant Infection
Noah Shopen, Michal Dekel, Michal Mizrahi, Efrat Zandberg, Nancy Bishouty, Daniel Talmud, Ben Vaknin, Shira Haberman, Malka Katz Shalhav, David Zeltser, Neta Cohen
medRxiv 2022.01.29.22270090; doi: https://doi.org/10.1101/2022.01.29.22270090
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area